Opendata, web and dolomites

STRICT SIGNED

SN: The first blood biomarker to accurately STratify mortality Risk In patients with Cardiac arrhyTmia

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 STRICT project word cloud

Explore the words cloud of the STRICT project. It provides you a very rough idea of what is the project "STRICT" about.

device    data    burden    cardiovascular    quality    difficult    lt    alone    ivd    35    positioning    51    victims    sudden    activated    trl8    surgery    eligible    echocardiogram    sn    market    unknowingly    mortality    health    global    left    maturation    globally    ejection    cvd    risk    patients    expertise    company    patient    biomarker    killer    secretoneurin    acquiring    assurance    house    status    sme    survival    linked    ecg    67    regime    stratify    lvef    cardiac    decision    never    exams    levels    skills    death    saving    boost    ventricle    coming    25    disease    accurate    diagnosis    reducing    detect    pinpoint    worldwide    cardinor    correlation    cardiologists    patented    least    cardioverter    overtreatment    physical    biomarkers    vitro    biomedical    implantable    20k    arrythmia    arrhythmias    diagnostic    lives    advantage    shown    ventricular    blood    3b    icds    associate    innovation    defibrillator    normal    icd    ask    scd    recruit    competitive    caused   

Project "STRICT" data sheet

The following table provides information about the project.

Coordinator
CARDINOR AS 

Organization address
address: GAUSTADALLEEN 21
city: OSLO
postcode: 349
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Norway [NO]
 Total cost 119˙805 €
 EC max contribution 119˙805 € (100%)
 Programme 1. H2020-EU.2.3.2.2. (Enhancing the innovation capacity of SMEs)
 Code Call H2020-INNOSUP-2019-02
 Funding Scheme CSA
 Starting year 2019
 Duration (year-month-day) from 2019-12-15   to  2020-12-14

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CARDINOR AS NO (OSLO) coordinator 119˙805.00

Map

 Project objective

Cardiovascular disease (CVD) is the no. 1 killer worldwide. 25% of all CVD mortality is caused by ventricular arrhythmias that lead to sudden cardiac death (SCD). The diagnosis of arrhythmias is difficult but crucial for accurate decision-making and patient survival. To assess the patient’s status, cardiologists currently ask: physical exams, some cardiac biomarkers data, an ECG (which may detect an arrythmia) and an echocardiogram to measure the blood ejection from the left ventricle (LVEF), since there is a correlation between LVEF and risk of ventricular arrhythmias. If LVEF is < 35%, the patient is eligible for implantable cardioverter-defibrillator (ICD) surgery, which costs at least 20K€. Still, around 51 % of victims of SCD have normal LVEF. In addition, 67% of all implemented ICDs are never activated because those patients were (unknowingly) at low-risk for arrhythmias, which represents a 1.3B€ overtreatment cost / year in the EU alone. CardiNor is bringing to market a new in vitro diagnostic (IVD) test to measure blood levels of Secretoneurin (SN), a globally patented biomarker and the only one shown to be specifically linked to ventricular arrhythmias. With SN data, cardiologists will be able to stratify patients according to their risk as well as to pinpoint high-risk patients not identified by the current diagnostic regime, thus reducing health burden costs and saving lives. CardiNor needs the SME Innovation Associate Programme to boost R&D activities within test maturation and effectively take it to TRL8. Currently, we do not have in-house expertise in biomedical device development or quality assurance. Therefore, we are looking to recruit an Innovation Associate. Acquiring these skills is important for CardiNor to maintain competitive advantage over coming years, positioning our company to high growth in the global CVD biomarkers market.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "STRICT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "STRICT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.3.2.2.)

INMANCAP 2020_21 (2020)

Enhancing innovation management capacity of SMEs in the Netherlands in 2020-2021

Read More  

EEN InnoSupp BG-4 (2020)

EEN InnoSupp BG-4

Read More  

BITNET INNOSUP (2020)

BITNET INNOSUP

Read More  
lastchecktime (2025-01-31 2:21:48) correctly updated